Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19

MT Newswires Live

2025/03/14

Inovio Pharmaceuticals (INO) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.

The company said all study participants "maintained biologically relevant levels of DMAbs" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.

The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca (AZN), and clinical investigators at the University of Pennsylvania.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2519820915"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519820915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519820915?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-14 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519820915","market":"us","top_or_hot":-1,"title":"Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19","media":"MT Newswires Live","content":"<html><body><p> Inovio Pharmaceuticals (INO) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.</p><p>The company said all study participants \"maintained biologically relevant levels of DMAbs\" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.</p><p>The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca (AZN), and clinical investigators at the University of Pennsylvania.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-14 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Inovio Pharmaceuticals (INO) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.</p><p>The company said all study participants \"maintained biologically relevant levels of DMAbs\" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.</p><p>The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca (AZN), and clinical investigators at the University of Pennsylvania.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特種化學制品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2519820915","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519820915","pubTimestamp":1741943864,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inovio Pharmaceuticals  said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.The company said all study participants \"maintained biologically relevant levels of DMAbs\" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca , and clinical investigators at the University of Pennsylvania.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4109":"特种化学制品","BK4588":"碎股","BK4568":"美国抗疫概念","INO":"伊诺维奥制药","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4007":"制药","BNTX":"BioNTech SE","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4583":"猴痘概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4585":"ETF&股票定投概念","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","DNA":"Ginkgo Bioworks Holdings Inc.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AZN":"阿斯利康","BK4139":"生物科技","LU1829250122.USD":"高盛欧洲核心股票组合Acc"},"translate_title":"Inovio Pharmaceuticals报告DNA编码的新冠肺炎单克隆抗体中期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"INO":1,"DNA":1,"BNTX":1},"content_text":"Inovio Pharmaceuticals (INO) said late Thursday that interim results from an ongoing phase 1 study of DNA-encoded monoclonal antibodies for COVID-19 demonstrated durable in vivo antibody production.The company said all study participants \"maintained biologically relevant levels of DMAbs\" at week 72. The DMAbs were also well tolerated and no participant developed anti-drug antibodies, Inovio added.The trial is led by the Wistar Institute in collaboration with Inovio, AstraZeneca (AZN), and clinical investigators at the University of Pennsylvania.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}